Medicare Part D spending on diabetes drugs increased 364% from 2019 to 2023, driven by GLP-1 and SGLT-2 inhibitors. Metformin spending decreased by 5%, contrasting with the surge in other diabetes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results